Similarly, pooled analyses from the ASCLEPIOS I/II, APLIOS, APOLITOS, and ALITHIOS trials concluded that there was no apparent association between low IgG or IgM levels with risk of serious infection after 3.5 years of treatment with ofatumumab [17]; 4-year data from ALITHIOS presented after this SLR was conducted have shown consistent results [13]. This evidence concerns the gene CD40LG and infection.